Articles from Sensome

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced successful Proof of Concept (POC) cases using its Clotild® Smart Guidewire System with commercial and next-generation robotic systems from Robocath, a global leader in robotic solutions dedicated to interventional cardiology, to access and characterize clot in cerebral blood vessels. The effort demonstrates the feasibility of using Sensome’s smart guidewire technology with any robotic system accessing the vasculature to provide valuable sensor-obtained biological intelligence that can enhance a procedure.

Sensome, the pioneer of microsensing technology for real-time, in situ tissue analysis, today announced publication of a study in Science Advances unveiling an innovative methodology using its technology to non-invasively monitor cell spatiotemporal dynamics involved in cancer progression in a real-time and label-free manner, which can provide new insights for cancer diagnosis and treatment.

Sensome, the pioneer of microsensing technology for real-time, intra-operative tissue analysis, announced today it has completed enrollment in the first-in-human INSPECT study of its novel technology, being developed to detect cancerous tissue in situ during transbronchial biopsy of endobronchial and peripheral tumors.

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced positive results from two studies of its Clotild® Smart Guidewire System demonstrating its ability to successfully identify “fresh” clot – thrombus rich in red blood cells (RBCs) – in peripheral artery disease (PAD) and differentiate it from other tissue encountered during PAD procedures. Results from the SEPARATE and E-SEPARATE studies were presented today in a late-breaking trial session at the Paris Vascular Insights Course.

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, announced today that the first eight patients have been enrolled in the first-in-human INSPECT study of its novel microsensor technology being developed to instantly detect cancerous tissue during transbronchial biopsy of endobronchial tumors and peripheral lung nodules.

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced an exclusive distribution agreement (the “Agreement”) in Japan with Cosmotec, an M3 Group company, for its smart clot-sensing guidewire used in mechanical thrombectomy. Cosmotec made an upfront investment in Sensome upon finalizing the Agreement.

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced positive results from its first-in-human CLOT OUT clinical trial evaluating the safety and performance of its Clotild® Smart Guidewire System used during mechanical thrombectomy treating ischemic stroke. The results showed that the technology met all primary safety and performance endpoints of the trial.1 There were no serious adverse events related to use of the Clotild device, and it successfully automated the identification of red blood cells (RBCs) and platelets in close alignment with human experts. The study was presented today at the renowned international LINNC Paris conference by Prof. Aymeric Rouchaud, principal investigator of the CLOT OUT study at CHU Limoges in France.

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD). Clotild® was designated a breakthrough medical device for use in brain arteries by the FDA in 2021.

Pioneering smart medical device company, Sensome, and world-leading Japanese guidewire company, Asahi Intecc, are announcing today a collaboration to develop the next generation Clotild® Smart Guidewire, with Asahi Intecc taking on the manufacturing role for this groundbreaking device destined for the treatment of acute ischemic stroke.

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that Gold Coast University Hospital (GCUH) in Australia enrolled the first patients in the Company’s CLOT OUT first-in-human study evaluating safety and performance of the Clotild® Smart Guidewire System in large-vessel acute ischemic stroke patients.

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its Clotild® Smart Guidewire System designed to improve the treatment of ischemic stroke patients.